COMP <GO>
HCM vs HRMY // FORWARD P/E MULTIPLE
HUTCHMED (China) Limited (NASDAQ) VS. Harmony Biosciences Holdings Inc. (NASDAQ) • 15-METRIC TALLY: HCM 3
— HRMY 7
▲ FORWARD P/E MULTIPLE LEADER: HCM
LAST: $13.27 (+0.91%) • MKT CAP: $2.29B
forward-pe
4.8x
LAST: $37.91 (-2.19%) • MKT CAP: $2.26B
forward-pe
11.9x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HCM VS. HRMY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HCM | HRMY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 77.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -2.50% | 63.00% | -65.50 | HRMY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 7.8x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.32% | 15.48% | -18.80 | HRMY | /fcf-yield <GO> |
| Operating Margin | -7.10% | 24.00% | -31.10 | HRMY | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 18.30% | +49.70 | HCM | /net-margins <GO> |
| Revenue Growth (YoY) | -13.00% | 21.50% | -34.50 | HRMY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.63 | 5.38 | -1.75 | HRMY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 9/9 | -5.00 | HRMY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.4 | 51.1 | -8.70 | HRMY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 4.8x | 11.9x | -7.10 | HCM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.29B | $2.26B | $37.0M | HCM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HCM REV | HRMY REV | HCM GROSS % | HRMY GROSS % | HCM FCF | HRMY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $548.5M | $868.5M | 38.7% | 77.2% | -$78.8M | $347.9M |
| FY 2024 | $630.2M | $714.7M | 44.6% | 78.1% | -$17.4M | $218.7M |
| FY 2023 | $838.0M | $582.0M | — | — | $219.3M | $219.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HCM // BETA —
HRMY // BETA —